ENDPOINTS

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA submission. It also brings to the fore an upcoming decision ...

Mar 3, 2025 - 17:29
 0
Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA submission. It also brings to the fore an upcoming decision ...
Read More

Tags:

Previous Article

Critical snowfall-to-precipitation ratios identified in high mountain Asia amid ...

Next Article

Organohalogen compounds in whale blubber provide window into marine habitats for...

Related Posts

Regeneron shakes up accelerated approval plans for lymphoma bispecific

Regeneron shakes up accelerated approval plans for lymp...

Feb 26, 2025  0

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Eli Lilly stockpiles $548M of oral weight loss drug ahe...

Feb 21, 2025  0

Pliant shares plummet as Phase 2b lung fibrosis study paused

Pliant shares plummet as Phase 2b lung fibrosis study p...

Feb 10, 2025  0